```
=> fil reg
FILE 'REGISTRY' ENTERED AT 10:24:44 ON 19 JAN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:   16 JAN 2002  HIGHEST RN 383858-27-3
DICTIONARY FILE UPDATES:  16 JAN 2002  HIGHEST RN 383858-27-3

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Calculated physical property data is now available.  See HELP PROPERTIES
for more information.  See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf
```

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov

```
=> d sta que l45
L43                 STR
```




```
NODE ATTRIBUTES:
CONNECT IS M2  RC AT  11
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  12

STEREO ATTRIBUTES: NONE
L45          1998 SEA FILE=REGISTRY CSS FUL L43

100.0% PROCESSED  14573 ITERATIONS                      1998 ANSWERS
SEARCH TIME: 00.00.01


=> d his

     (FILE 'HOME' ENTERED AT 09:13:07 ON 19 JAN 2002)
               SET COST OFF

     FILE 'HCAPLUS' ENTERED AT 09:13:17 ON 19 JAN 2002
               E WACHER V/AU
L1            19 S E4-E6
               E BENET L/AU
L2           420 S E3,E5-E7
L3           911 S GALLIC ACID (L) ESTER?
L4          1710 S (EPICATECHIN OR EPIGALLOCATECHIN OR GALLOCATECHIN)(L)GALLATE
L5             9 S EPI()(CATECHIN OR GALLOCATECHIN OR GALLO()CATECHIN)(L)GALLATE
```

```
L6            4 S GALLO()CATECHIN(L)GALLATE
L7         5821 S TANNIC ACID
               E TANNIN/CT
               E E39+ALL
L8          138 S  E9
L9        10753 S E8
L10         297 S E33-E38

     FILE 'REGISTRY' ENTERED AT 09:19:10 ON 19 JAN 2002
L11           3 S 863-03-6 OR 989-51-5 OR  4233-96-9
               E C22H18O10/MF
L12          67 S E3
L13          34 S E18
L14         101 S L12,L13
L15          40 S L14 AND 46.150.18/RID AND OC5-C6/ES AND 4/NR
L16          31 S L15 NOT IDS/CI
L17          29 S L16 AND 3 4 5 TRIHYDROXY
L18          19 S L17 AND 5 7 DIHYDROXY
L19           8 S L18 AND 3 4 DIHYDROXY

     FILE 'REGISTRY' ENTERED AT 09:24:02 ON 19 JAN 2002

     FILE 'REGISTRY' ENTERED AT 09:24:42 ON 19 JAN 2002

     FILE 'REGISTRY' ENTERED AT 09:25:32 ON 19 JAN 2002
L20           7 S L19 NOT 213598-38-0
L21          11 S L18 NOT L19

     FILE 'REGISTRY' ENTERED AT 09:26:48 ON 19 JAN 2002
L22           7 S L21 NOT (D OR T)/ELS
L23          14 S L11,L20,L22
               SEL RN
L24          14 S E1-E14/CRN

     FILE 'HCAPLUS' ENTERED AT 09:31:12 ON 19 JAN 2002
L25        1627 S L23
L26           9 S L24
L27           6 S L26 AND (1 OR 63 OR 26)/SC,SX
L28           3 S L26 NOT L27

     FILE 'REGISTRY' ENTERED AT 09:33:09 ON 19 JAN 2002
L29           1 S 149-91-7

     FILE 'HCAPLUS' ENTERED AT 09:33:14 ON 19 JAN 2002
L30         373 S L29/D
L31         163 S L29 (L) ESTER
L32         114 S L30 AND L31
L33          49 S L31 NOT L32
L34           1 S L33 AND 63/SC
L35        8544 S L32,L34,L25,L3-L8
L36       16809 S L9,L35
L37       16838 S L10,L36
L38           2 S L1,L2 AND L37
               E ANMAX/PA,CS
L39           1 S E3-E6
               E AVMAX/PA,CS
L40          12 S E3-E9
L41           2 S L37 AND L39,L40
L42           2 S L38,L41

     FILE 'REGISTRY' ENTERED AT 09:37:55 ON 19 JAN 2002
L43             STR
L44          50 S L43 CSS
L45        1998 S L43 CSS FUL
               SAV L45 KWON914/A
L46        1970 S L45 NOT L23,L24,L29
```

```
L47             STR L43
L48           8 S L47 CSS SAM SUB=L46
L49         160 S L47 CSS FUL SUB=L46
                SAV L49 KWON914A/A
L50          83 S L49 AND 1/NC
L51          74 S L50 NOT IDS/CI
L52          77 S L49 NOT (L50  OR IDS/CI)
L53          63 S L52 NOT (MNS OR PMS)/CI
L54           4 S C6H8O6 AND L46
L55        1892 S L46 NOT L51,L54

     FILE 'HCAPLUS' ENTERED AT 09:47:19 ON 19 JAN 2002
L56           2 S L54
L57        3093 S L51
L58           3 S L1,L2,L39,L40 AND L57
L59           3 S L42,L58

     FILE 'REGISTRY' ENTERED AT 09:52:59 ON 19 JAN 2002

     FILE 'HCAPLUS' ENTERED AT 09:53:34 ON 19 JAN 2002
                SET SMARTSELECT ON
L60         SEL L59 1- RN :      58 TERMS
                SET SMARTSELECT OFF

     FILE 'REGISTRY' ENTERED AT 09:53:34 ON 19 JAN 2002
L61          58 S L60
L62           3 S L61 AND L23,L24
L63          13 S L61 AND L57
L64          13 S L61 AND L46
L65           1 S L61 AND L29
L66          17 S L62-L65
L67          41 S L61 NOT L66
L68          40 S L67 NOT CYTOCHROME
L69           1 S L67 NOT L68

     FILE 'HCAPLUS' ENTERED AT 10:10:00 ON 19 JAN 2002
L70      153676 S L68
L71         385 S L70 AND L37
L72         183 S L70 AND L57
L73         538 S L71,L72
L74       31335 S L69
L75           2 S L72,L73 AND L74
                E DRUG BIOAVAILABILITY/CT
                E E3+ALL
L76       12132 S E3
                E E1+ALL
L77         154 S E1
                E E2+ALL
                E E6+ALL
L78        3184 S E5,E4+NT
                E E9+ALL
L79        4162 S E2
                E DRUG BIOAVAILABILITY/CT
                E E3+ALL
                E E7+ALL
L80        2154 S E5+NT
                E E10+ALL
L81       19429 S L37,L57
L82          19 S L81 AND L76,L77
L83           7 SS L81 AND L78-L80
L84          25 S L82,L83
L85          16 S L84 NOT P/DT
                SEL DN 1-4
L86          12 S L85 NOT E1-E4
L87           1 S L86 AND TANNIC ACID COMPLEX
L88          12 S L27,L56,L59,L87
```

```
L89            6 S L84 NOT L85,L88
                 SEL DN 1 2 6
L90            3 S L89 AND E5-E7
L91           15 S L88,L90
L92           15 S L91 AND L1-L10,L25-L28,L30-L42,L56-L59,L70-L91

     FILE 'REGISTRY' ENTERED AT 10:24:44 ON 19 JAN 2002

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 10:24:56 ON 19 JAN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1907 - 19 Jan 2002  VOL 136 ISS 4
FILE LAST UPDATED: 17 Jan 2002  (20020117/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

 This file supports REGlstRY for direct browsing and searching of
 all substance data from the REGISTRY file.  Enter HELP FIRST for
 more information.

HCAplus now provides online access to patents and literature
covered in CA from 1907 to the present.  Bibliographic
information and abstracts were added in 2001 for over 3.8
million records from 1907-1966.

CAS roles have been modified effective December 16, 2001. Please
check your SDI profiles to see if they need to be revised. For
information on CAS roles, enter HELP ROLES at an arrow prompt or use
the CAS Roles thesaurus (/RL field) in this file.


=> d all tot 192

L92  ANSWER 1 OF 15  HCAPLUS  COPYRIGHT 2002 ACS
AN   2001:923593  HCAPLUS
DN   136:42866
TI   Bioavailable dosage form of isotretinoin
IN   Pant, Abha; Bhatia, Inderdeep; Roy, Sunilendu Bhushan; Malik, Rajiv
PA   Ranbaxy Laboratories Limited, India
SO   PCT Int. Appl., 14 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
IC   ICM  A61K009-14
     ICS  A61K009-48; A61K031-20
CC   63-6 (Pharmaceuticals)
     Section cross-reference(s): 1
FAN.CNT 1
     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
PI   WO 2001095886      A1   20011220      WO 2001-IB581    20010409
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
             HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
             RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
```

VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI IN 2000-DE596 A 20000616

AB The present invention relates to a bioavailable pharmaceutical compn. of 13-cis-vitamin A acid (also known as 13-cis-retinoic acid and isotretinoin) and a process for prepg. the same. 13-Cis-vitamin A acid is a relatively water-insol. compd. that degrades when exposed to light and atm. oxygen. Due to its instability and relative insoly., the bioavailability of the drug after oral administration is difficult to achieve and has always been a challenge to a development pharmacist. It would therefore be desirable to provide a dosage form in which the drug is stable and predictably bioavailable. Thus, soft gelatin capsules contained isotretinoin 40, wax mixt. [hydrogenated soybean oil, white wax and hydrogenated vegetable oil (1:1.2:4.2)] 97.86, BHT 0.032, disodium diedetate 0.160, and soybean oil 181.0 mg.,.

ST isotretinoin bioavailable pharmaceutical; vitamin A acid bioavailable pharmaceutical

IT Antioxidants
Beeswax
Drug bioavailability
Drug delivery systems
Particle size distribution
Surface area
(bioavailable dosage form of isotretinoin)

IT Chelates
Cottonseed oil
Paraffin oils
Peanut oil
Polyoxyalkylenes, biological studies
Soybean oil
Tocopherols
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bioavailable dosage form of isotretinoin)

IT Drug delivery systems
(capsules; bioavailable dosage form of isotretinoin)

IT Soybean oil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogenated; bioavailable dosage form of isotretinoin)

IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sesame; bioavailable dosage form of isotretinoin)

IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vegetable, hydrogenated; bioavailable dosage form of isotretinoin)

IT 4759-48-2, Isotretinoin
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bioavailable dosage form of isotretinoin)

IT 62-33-9, Calcium Disodium edetate **121-79-9**, Propyl gallate 128-37-0, BHT, biological studies 137-66-6, Ascorbyl palmitate 139-33-3, Disodium edetate 25013-16-5, BHA 25322-68-3, Polyethylene glycol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bioavailable dosage form of isotretinoin)

RE.CNT 3

RE
(1) La Roche, H; WO 0025772 A 2000 HCAPLUS
(2) Ortho Pharma Corp; EP 0184942 A 1986 HCAPLUS
(3) Straw, G; US 4808630 A 1989 HCAPLUS

L92 ANSWER 2 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 2001:617777 HCAPLUS
DN **135:175411**
TI Polyhydroxylated benzene-containing compounds for reducing food intake in

a subject
IN Liao, Shutsung; Hiipakka, Richard A.; Kao, Yung-Hsi
PA Arch Development Corporation, USA
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 1-11 (Pharmacology)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060319	A2	20010823	WO 2001-US4915	20010215

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-183668 A2 20000218
OS MARPAT 135:175411
AB A method for reducing food intake in a subject and a method for reducing the levels of an endocrine in a subject. The methods include administering to the subject in need thereof an effective amt. of a polyhydroxylated benzene-contg. compds. Also disclosed is a liposomal prepn. which includes a liposome and a compd. entrapped therein.
ST benzene polyhydroxylated appetite depressant antiobesity agent
IT Blood
(chem.; prepn. of polyhydroxylated benzene-contg. compds. for reducing food intake in a subject and antiobesity activity)
IT Phosphatidylcholines, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(complexes with polyhydroxylated benzenes; prepn. of polyhydroxylated benzene-contg. compds. for reducing food intake in a subject and antiobesity activity)
IT Drug delivery systems
(liposomes; prepn. of polyhydroxylated benzene-contg. compds. for reducing food intake in a subject and antiobesity activity)
IT Antiobesity agents
Appetite depressants
Drug bioavailability
Eosinophil
Lymphocyte
Monocyte
Platelet (blood)
(prepn. of polyhydroxylated benzene-contg. compds. for reducing food intake in a subject and antiobesity activity)
IT Hemoglobins
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(prepn. of polyhydroxylated benzene-contg. compds. for reducing food intake in a subject and antiobesity activity)
IT Organ, animal
Reproductive organ
(wt. change; prepn. of polyhydroxylated benzene-contg. compds. for reducing food intake in a subject and antiobesity activity)
IT **989-51-5** 131580-20-6 355374-17-3 355374-18-4 355374-19-5 355374-20-8
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of polyhydroxylated benzene-contg. compds. for reducing food intake in a subject and antiobesity activity)
IT 9002-67-9, LH 9002-72-6, GH 67763-96-6, IGF-I 169494-85-3, Leptin
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)

(prepn. of polyhydroxylated benzene-contg. compds. for reducing food intake in a subject and antiobesity activity)

IT 610-02-6, 2,3,4-Trihydroxybenzoic acid 7699-31-2 32064-67-8, tert-Butylhydrazine
RL: RCT (Reactant)
(prepn. of polyhydroxylated benzene-contg. compds. for reducing food intake in a subject and antiobesity activity)

IT 355374-15-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of polyhydroxylated benzene-contg. compds. for reducing food intake in a subject and antiobesity activity)

IT 355374-14-0P 355374-16-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of polyhydroxylated benzene-contg. compds. for reducing food intake in a subject and antiobesity activity)

L92 ANSWER 3 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 2001:161509 HCAPLUS
DN 134:202683
TI Methods using a tea catechin for treating papilloma virus-associated hyperplasia
IN Cheng, Shu Jun; Wang, De Chang; Hara, Yukihiko; Lee, Insu P.; Ahn, Woong Shick
PA Cancer Instititute (Hospital), Chinese Academy of Medical Sciences, Peop. Rep. China; Mitsui Norin Co., Ltd.
SO U.S., 4 pp., Cont.-in-part of U.S. 5,968,973.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-35
NCL 514456000
CC **1-6** (Pharmacology)
Section cross-reference(s): **63**

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6197808	B1	20010306	US 1999-418890	19991015
	US 5795911	A	19980818	US 1997-835920	19970410
	US 5968973	A	19991019	US 1998-56378	19980407
PRAI	US 1997-835920	A2	19970410		
	JP 1997-321195	A	19970915		
	US 1998-56378	A2	19980407		
	JP 1996-321195	A	19961118		

AB A method for a treatment of hyperplasia caused by papilloma virus, such as Condyloma acuminata, comprises concomitantly topically and orally administering at least one tea catechin. Tea catechins do not involve the risk of side-effects and may be easily administered by the patients themselves.

ST tea catechin papillomavirus hyperplasia; Condyloma acuminata tea catechin

IT Reproductive tract
(acuminate wart; tea catechin for treating papilloma virus-assocd. hyperplasia)

IT Drug delivery systems
(capsules; tea catechin for treating papilloma virus-assocd. hyperplasia)

IT Antitumor agents
(cervix carcinoma; tea catechin for treating papilloma virus-assocd. hyperplasia)

IT Uterus, neoplasm
(cervix, carcinoma, inhibitors; tea catechin for treating papilloma virus-assocd. hyperplasia)

IT Uterus, neoplasm
(cervix, carcinoma, intraepithelial; tea catechin for treating papilloma virus-assocd. hyperplasia)

IT Cell proliferation
(inhibitors; tea catechin for treating papilloma virus-assocd.

hyperplasia)
IT Drug delivery systems
(ointments, creams; tea catechin for treating papilloma virus-assocd. hyperplasia)
IT Drug delivery systems
(ointments; tea catechin for treating papilloma virus-assocd. hyperplasia)
IT Drug delivery systems
(oral; tea catechin for treating papilloma virus-assocd. hyperplasia)
IT Drug delivery systems
(suppositories; tea catechin for treating papilloma virus-assocd. hyperplasia)
IT Hyperplasia
Papillomavirus
Tea products
(tea catechin for treating papilloma virus-assocd. hyperplasia)
IT Flavanols
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tea catechin for treating papilloma virus-assocd. hyperplasia)
IT Drug delivery systems
(topical; tea catechin for treating papilloma virus-assocd. hyperplasia)
IT Drug delivery systems
(vaginal; tea catechin for treating papilloma virus-assocd. hyperplasia)
IT 970-74-1, (-)-Epigallocatechin 136511-29-0, Polyphenon 100 246537-81-5, Polyphenol E **328240-61-5**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tea catechin for treating papilloma virus-assocd. hyperplasia)
RE.CNT 16
RE
(1) Anon; DE 2206570 1972 HCAPLUS
(2) Anon; JP 03141220 A 1991 HCAPLUS
(3) Anon; EP 0417385 1991 HCAPLUS
(4) Anon; DE 4211238 1993 HCAPLUS
(5) Anon; GB 2293548 1996
(6) Anon; WO 9628178 1996 HCAPLUS
(7) Bombardelli; US 5605929 1997 HCAPLUS
(8) Bombardelli; US 5648377 1997 HCAPLUS
(9) Cheng; US 5795911 1998 HCAPLUS
(10) Hirayama; US 5159069 1992 HCAPLUS
(11) Hirose; Cancer Letters 1994, V83(1-2), P149 HCAPLUS
(12) Mukhtar; Green Tea and Skin-Anticarcinogenic Effects 1994, V102(1), P3 MEDLINE
(13) Shimamura; US 5135957 1992 HCAPLUS
(14) Stich; Mutation Research 1990, V241(4), P387 HCAPLUS
(15) Tempesta; US 5211944 1993 HCAPLUS
(16) Williams; US 5576013 1996 HCAPLUS

L92 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 2001:75302 HCAPLUS
DN 134:136674
TI Use of **gallic acid esters** to increase bioavailability of orally administered pharmaceutical compounds
IN **Wacher, Vincent J.; Benet, Leslie Z.**
PA **Anmax, Inc., USA**
SO U.S., 12 pp., Cont.-in-part of U.S. 5,962,522.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-235
ICS A61K031-353
NCL 514544000
CC 63-5 (Pharmaceuticals)

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6180666	B1	20010130	US 1999-264215	19990305
	US 5962522	A	19991005	US 1997-926309	19970905
	WO 2000051643	A1	20000908	WO 2000-US5524	20000301
	W: AU, CA, JP, NZ, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1159007	A1	20011205	EP 2000-912149	20000301
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	US 1997-926309	A2	19970905		
	US 1999-264215	A	19990305		
	WO 2000-US5524	W	20000301		

OS MARPAT 134:136674

AB A method is disclosed for increasing bioavailability of an orally administered pharmaceutical compd. comprising orally coadministering the pharmaceutical compd. to a mammal in need of treatment with the compd. and a **gallic acid ester**. Preferred **gallic acid esters** of the invention include octyl gallate, Pr gallate, lauryl gallate, and Me gallate. Improved formulations of pharmaceutical compds. include the **gallic acid ester** to enhance the bioavailability of the active ingredient of the pharmaceutical compd. Octyl gallate at 100 .mu.M decreased the relative nifedipine oxidn. of CYP3A metab. in human liver microsome from 100 to 1.1.

ST gallic ester bioavailability oral pharmaceutical

IT Rauvolfia
(alkaloids; use of **gallic acid esters** to increase bioavailability of orally administered pharmaceutical compds.)

IT Antibiotics
(anthracycline; use of **gallic acid esters** to increase bioavailability of orally administered pharmaceutical compds.)

IT Estrogens
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiestrogens; use of **gallic acid esters** to increase bioavailability of orally administered pharmaceutical compds.)

IT Peptides, biological studies
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclic; use of **gallic acid esters** to increase bioavailability of orally administered pharmaceutical compds.)

IT Natural products, pharmaceutical
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(digitalis; use of **gallic acid esters** to increase bioavailability of orally administered pharmaceutical compds.)

IT Alkaloids, biological studies
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ergot; use of **gallic acid esters** to increase bioavailability of orally administered pharmaceutical compds.)

IT Amines, biological studies
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phenylalkyl; use of **gallic acid esters** to increase bioavailability of orally administered pharmaceutical compds.)

IT **Drug bioavailability**
(use of **gallic acid esters** to increase bioavailability of orally administered pharmaceutical compds.)

IT Anilides

Cannabinoids
Glycosides
Hydrocarbons, biological studies
Macrolides
Opioids
Retinoids
Steroids, biological studies
Sulfones
Sulfonylureas
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of **gallic acid esters** to increase bioavailability of orally administered pharmaceutical compds.)

IT Alkaloids, biological studies
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vinca; use of **gallic acid esters** to increase bioavailability of orally administered pharmaceutical compds.)

IT **55-86-7**, Nitrogen mustard, **64-86-8**, Colchicine, **69-72-7**, biological studies **91-20-3**, Naphthalene, biological studies **91-22-5D**, Quinoline, derivs. **92-84-2D**, Phenothiazine, derivs. **103-84-4**, Acetanilide **106-51-4D**, Quinone, derivs. **110-85-0D**, Piperazine, derivs. **110-86-1D**, Pyridine, derivs. **110-89-4**, Piperidine, biological studies **119-65-3**, Isoquinoline **123-75-1D**, Pyrrolidine, derivs. **253-82-7D**, Quinazoline, derivs. **256-96-2**, 5H-Dibenz[b,f]azepine **271-89-6**, Benzofuran **288-32-4**, Imidazole,, biological studies **288-42-6D**, Oxazole, derivs. **289-95-2D**, Pyrimidine, derivs. **478-88-6**, Ergoline **529-17-9**, Tropane **588-59-0**, Stilbene **4375-07-9**, Epipodophyllotoxin **11084-05-2D**, Oxazine, derivs. **11111-12-9**, Cephalosporin **27254-80-4**, Aminoacridine **27790-75-6**, Dihydropyridine, **28261-54-3**, Pyrrolidinone **28261-54-3D**, Pyrrolidinone, derivs. **31135-62-3**, Aminoquinoline **33069-62-4**, Paclitaxel **37306-44-8D**, Triazole, derivs.
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of **gallic acid esters** to increase bioavailability of orally administered pharmaceutical compds.)

IT **99-24-1**, Methyl gallate. **121-79-9**, Propyl gallate **149-91-7D, Gallic acid, esters** **1034-01-1**, Octyl gallate **1166-52-5**, Lauryl gallate **15674-66-5 36362-22-8 291506-30-4 291506-31-5 291506-33-7 291506-34-8 291506-35-9 291506-36-0**
RL: BPR (Biological process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(use of **gallic acid esters** to increase bioavailability of orally administered pharmaceutical compds.)

RE.CNT 30
RE
(1) Anon; GB 997914 1965 HCAPLUS
(2) Anon; EP 0184942 A2 1986 HCAPLUS
(3) Anon; EP 0295941 B1 1988 HCAPLUS
(4) Anon; EP 0314384 A2 1989 HCAPLUS
(5) Anon; WO 9520980 1995 HCAPLUS
(6) Anon; WO 9601128 1996 HCAPLUS
(7) Anon; WO 9640192 1996 HCAPLUS
(8) Apostolides, Z; Mutation Research 1997, V389(2-3), P167 MEDLINE
(9) Baer-Dubowska, W; Xenobiotica 1998, V28(8), P735 HCAPLUS
(10) Bamforth, K; Biochem Pharmacol 1993, V46(10), P1713 HCAPLUS
(11) Benet; US 5567592 1996 HCAPLUS
(12) Benet; US 5665386 1997 HCAPLUS
(13) Bernard; US 3282789 1966 HCAPLUS
(14) Bonkovsky; Gastroenterology 1985, V88, P458 HCAPLUS

(15) Bourrie, M; J Pharmacol Exp Ther 1996, V277(1), P321 HCAPLUS
(16) Bradford, M; Anal Biochem 1976, V72, P248 HCAPLUS
(17) Burke, M; Biochem Pharmacol 1985, V34(18), P337
(18) Clarke, S; Xenobiotica 1994, V24, P517 HCAPLUS
(19) Fabre, G; Drug Metab Dispos 1993, V21(6), P978 HCAPLUS
(20) Fasco; Mol Pharmacol 1993, V43, P226 HCAPLUS
(21) Gallo-Torres; US 4310543 1982 HCAPLUS
(22) Gonzalez, F; DNA 1988, V7(2), P79 HCAPLUS
(23) Greenblatt, D; J Clin Pharmacol 1993, V33, P650 MEDLINE
(24) Kaminsky; Toxicology 1992, V21(6), P407 HCAPLUS
(25) Kedderis, G; J Biol Chem 1980, V255(21), P10174 HCAPLUS
(26) Kedderis, G; Microsomes, Drug Oxic, Chem Carcinoq, Int Symp Microsomes Drug Oxid 1980, V1, P351 HCAPLUS
(27) Kelleher, J; Biochem Soc Transact 1976, V4, P292 HCAPLUS
(28) Kelleher, J; J Ind Med Res 1976, V4(suppl 4), P138
(29) Mulligan; US 5156842 1992 HCAPLUS
(30) Salantinjants; US 4716173 1987 HCAPLUS

L92 ANSWER 5 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 2000:628027 HCAPLUS
DN 133:227794
TI Use of **gallic acid esters** to increase bioavailability of orally administered pharmaceutical compounds
IN **Wacher, Vincent J.; Benet, Leslie Z.**
PA **Avmax, Inc., USA**
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K047-14
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000051643	A1	20000908	WO 2000-US5524	20000301
W: AU, CA, JP, NZ, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6180666	B1	20010130	US 1999-264215	19990305
EP 1159007	A1	20011205	EP 2000-912149	20000301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI US 1999-264215	A	19990305		
US 1997-926309	A2	19970905		
WO 2000-US5524	W	20000301		

OS MARPAT 133:227794
AB A method for increasing bioavailability of an orally administered pharmaceutical compd. comprises orally coadministering the pharmaceutical compd. to a mammal in need of treatment with the compd. and a **gallic acid ester**. Preferred **gallic acid esters** of the invention include octyl **gallate**, Pr **gallate**, lauryl **gallate**, and Me **gallate**. Improved formulations of pharmaceutical compds. include the **gallic acid ester** to enhance the bioavailability of the active ingredient of the pharmaceutical compd. Examples were given for inhibition of drug degrdn. by **gallic acid esters** and inhibition of nifedipine degrdn. by heterocyclic **gallic acid esters** such as (-)-**epicatechin gallate**.
ST gallate ester oral drug bioavailability
IT Peptides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclic; **gallic acid esters** to increase bioavailability of oral pharmaceuticals)
IT Alkaloids, biological studies

Cannabinoids
Glycosides
Retinoids
Steroids, biological studies
Sulfonylureas
Tannins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**gallic acid esters** to increase bioavailability of oral pharmaceuticals)

IT Chloramines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitrogen mustards; **gallic acid esters** to increase bioavailability of oral pharmaceuticals)

IT **Drug bioavailability**
(oral; **gallic acid esters** to increase bioavailability of oral pharmaceuticals)

IT **99-24-1**, Methyl gallate **1034-01-1**, Octyl gallate **1166-52-5**, Lauryl gallate
RL: BPR (Biological process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(**gallic acid esters** to increase bioavailability of oral pharmaceuticals)

IT **64-86-8**, Colchicine **103-84-4**, Acetanilide **989-51-5**, (-)-**Epigallocatechin gallate** **1257-08-5 4233-96-9**, (-)-**Gallocatechin gallate 11111-12-9**, Cephalosporin **12794-10-4D**, Benzodiazepine, derivs. **15674-66-5 36362-22-8 291506-30-4 291506-31-5 291506-32-6 291506-33-7 291506-34-8 291506-35-9 291506-36-0**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**gallic acid esters** to increase bioavailability of oral pharmaceuticals)

RE.CNT 9
RE
(1) Avmax Inc; WO 9640192 A 1996 HCAPLUS
(2) Avmax Inc; WO 9911290 A 1999 HCAPLUS
(3) Baer-Dubowska, W; XENOBIOTICA 1998, V28(8), P735 HCAPLUS
(4) Neisler Laboratories Inc; GB 997914 A 1965 HCAPLUS
(5) Neisler Laboratories Inc; US 3282789 A 1966 HCAPLUS
(6) Obermeier, M; XENOBIOTICA 1995, V25(6), P575 HCAPLUS
(7) Salatinjants Aida; US 4716173 A 1987 HCAPLUS
(8) Schering Ag; WO 9601128 A 1996 HCAPLUS
(9) Wacher, V; JOURNAL OF PHARMACEUTICAL SCIENCES 1998, V87(11), P1322 HCAPLUS

L92 ANSWER 6 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 1999:184156 HCAPLUS
DN 130:227711
TI Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
IN **Wacher, Vincent J.; Benet, Leslie Z.**
PA **Avmax, Inc., USA**
SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K047-14
CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 1

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9911290	A1	19990311	WO 1998-US18444	19980903

W: CA, JP
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

US 5962522 A 19991005 US 1997-926309 19970905
EP 1009437 A1 20000621 EP 1998-946843 19980903
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
JP 2001514234 T2 20010911 JP 2000-508391 19980903
PRAI US 1997-926309 A 19970905
WO 1998-US18444 W 19980903

AB A method for increasing bioavailability of an orally administered pharmaceutical compd. comprises orally administering the pharmaceutical compd. to a mammal in need of treatment with the compd. concurrently with Pr gallate. Improved formulations of pharmaceutical compds. include Pr gallate to enhance the bioavailability of the active ingredient of the pharmaceutical compd. Pr gallate at 100 .mu.M decreased CYP3A-mediated metab. of amiodarone in human liver microsomes to 17% of the controls.

ST propyl gallate bioavailability oral pharmaceutical amiodarone

IT Natural products (pharmaceutical)
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(digitalis; use of Pr gallate to increase bioavailability of orally administered pharmaceutical compds.)

IT Alkaloids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ergot; use of Pr gallate to increase bioavailability of orally administered pharmaceutical compds.)

IT Alkaloids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(of Rauwolfia; use of Pr gallate to increase bioavailability of orally administered pharmaceutical compds.)

IT Amines, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phenylalkyl; use of Pr gallate to increase bioavailability of orally administered pharmaceutical compds.)

IT Antibiotics
Drug bioavailability
Drug delivery systems
(use of Pr gallate to increase bioavailability of orally administered pharmaceutical compds.)

IT Anilides
Anthracyclines
Antiestrogens
Cannabinoids
Cyclic peptides
Macrolides
Opioids
Polycyclic aromatic hydrocarbons
Retinoids
Steroids, biological studies
Sulfones
Sulfonylureas
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of Pr gallate to increase bioavailability of orally administered pharmaceutical compds.)

IT Alkaloids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vinca; use of Pr gallate to increase bioavailability of orally administered pharmaceutical compds.)

IT **121-79-9**, Propyl gallate
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of Pr gallate to increase bioavailability of orally administered pharmaceutical compds.)

IT **9035-51-2D**, Cytochrome p450, inhibitors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(use of Pr gallate to increase bioavailability of orally administered pharmaceutical compds.)

IT **55-86-7**, Nitrogen mustard **64-86-8**, Colchicine
69-72-7D, derivs. **91-20-3**, Naphthalene, biological

studies **91-22-5**, Quinoline, biological studies **92-84-2**
, Phenothiazine **103-84-4**, Acetanilide **106-51-4**,
Quinone, biological studies **110-85-0**, Piperazine, biological
studies **110-86-1**, Pyridine, biological studies **110-89-4**
, Piperidine, biological studies **119-65-3**, Isoquinoline
123-75-1, Pyrrolidine, biological studies **253-82-7**,
Quinazoline **256-96-2**, 5H-Dibenz[b,f]azepine **264-54-0**,
1H-1-Benzazepine **271-89-6**, Benzofuran **288-32-4**,
Imidazole, biological studies **288-42-6**, Oxazole **289-95-2**
, Pyrimidine **290-04-0**, 2H-1,3-Oxazine **478-88-6**,
Ergoline **529-17-9**, Tropane **588-59-0**, Stilbene
1951-25-3, Amiodarone **4096-20-2 4375-07-9**,
Epipodophyllotoxin **4471-17-4D**, Benzhydryl, compds.
11111-12-9, Cephalosporin **12794-10-4**, Benzodiazepine
21829-25-4, Nifedipine **27254-80-4**, Aminoacridine
27790-75-6, Dihydropyridine **28261-54-3**, Pyrrolidinone
31135-62-3, Aminoquinoline **33069-62-4**, Taxol
36505-84-7, Buspirone **37306-44-8**, Triazole
37342-64-6, Pyridone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of Pr gallate to increase bioavailability of orally administered
pharmaceutical compds.)

RE.CNT 6
RE
(1) Kedderis, G; JOURNAL OF BIOLOGICAL CHEMISTRY 1980, V255(21), P10174 HCAPLUS
(2) Kedderis, G; MICROSOMES, DRUG OXID, CHEM CARCINOG, INT SYMP MICROSOMES DRUG OXID, 4TH 1980, V1, P351 HCAPLUS
(3) Leslie, B; US 5567592 A 1996 HCAPLUS
(4) Ortho Pharma Corp; EP 0184942 A 1986 HCAPLUS
(5) Raychem Corp; EP 0314384 A 1989 HCAPLUS
(6) Yang, C; BIOCHEM PHARMACOL 1974, V23(22), P3129 HCAPLUS

L92 ANSWER 7 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 1998:95043 HCAPLUS
DN 128:221622
TI Enhancement of antitumor efficacy with tea catechins and/or theaflavins and antitumor agents with enhanced efficacy
IN Chen, Shu Jun; Wong, De Chang; Zen, Yon Su; Nishino, Sukeyoku; Hara, Yukihiko
PA Mitsui Norin Co., Ltd., Japan; Cancer Institute of Medical Biotechnology, Chinese Academy of Medical Scienc; Institute of Medical Biotechnology, Chinese Academy of Medical Science
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K031-35
ICS A61K031-35; A61K031-505; A61K031-70; A61K045-00; A61K035-78; C07D311-62
CC **63-5** (Pharmaceuticals)
Section cross-reference(s): **1**

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10036260	A2	19980210	JP 1996-206361	19960718
	EP 819433	A2	19980121	EP 1996-120973	19961228
	EP 819433	A3	19990512		
	R: BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	AU 9676515	A1	19980129	AU 1996-76515	19961230
	AU 690863	B2	19980430		
	CA 2195606	AA	19980119	CA 1997-2195606	19970121
	CN 1171238	A	19980128	CN 1997-102362	19970130
	US 5804567	A	19980908	US 1997-919716	19970827
PRAI	JP 1996-206361		19960718		
	US 1996-770553		19961223		

AB Efficacy of antitumor agents are enhanced upon adding tea catechins and/or

teaflavins. Also claimed are antitumor agents whose efficacy is enhanced as described above. Combined administration of cytarabine and **epigallocatechin gallate** to mice bearing leukemia L 1210 significantly prolonged the survival rate after 60 days.

ST antitumor efficacy enhancement tea catechin teaflavin; cytarabine antitumor efficacy enhancement **epigallocatechin gallate** ; methotrexate antitumor efficacy enhancement **epigallocatechin gallate**

IT Nutrients
(anti-; enhancement of antitumor activity with tea catechins and/or theaflavins)

IT Antitumor agents
Synergistic drug interactions
(enhancement of antitumor activity with tea catechins and/or theaflavins)

IT Flavanols
Polyphenols (nonpolymeric)
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enhancement of antitumor activity with tea catechins and/or theaflavins)

IT **863-03-6, Epicatechin gallate** 970-74-1, Epigallocatechin **989-51-5, Epigallocatechin gallate** 33377-72-9, Theaflavin digallate **204137-25-7** **204137-26-8**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enhancement of antitumor activity with tea catechins and/or theaflavins)

L92 ANSWER 8 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 1997:101120 HCAPLUS
DN 126:242804
TI Hydrogels for ocular delivery of pilocarpine. Preliminary evaluation in rabbits of the influence of viscosity and of drug solubility
AU Burgalassi, Susi; Chetoni, Patrizia; Saettone, M. Fabrizio
CS Dep. Pharmaceutical Technol. Biopharmacy, Univ. Pisa, Pisa, Italy
SO Eur. J. Pharm. Biopharm. (1996), 42(6), 385-392
CODEN: EJPBEL; ISSN: 0939-6411
PB Wissenschaftliche Verlagsgesellschaft
DT Journal
LA English
CC 63-6 (Pharmaceuticals)
AB Two distinct approaches, mucoadhesion and reduced drug soly., were applied to develop improved hydrogels for delivery of pilocarpine. Xyloglucan gum, xanthan gum, pectin, hydroxypropyl Me cellulose, and polyvinyl alc. were used at various concns. to prep. 2 series of iso-viscous hydrogels (series 1 and 2) characterized by apparent (pseudoplastic) viscosities of 0.03 and 6.00 Pas at a shear rate of 1.0 s-1. The more viscous gels (series 2), tested in vitro for adhesion on hog gastric mucin, showed high work of adhesion values. Both series contained pilocarpine as the nitrate (2.0% wt./wt.), while a 3rd hydrogel series, having the same polymer compn. and viscosity as series 2, contained pilocarpine as a poorly sol. **tannic acid complex**. All hydrogels were tested in vivo on rabbits for pilocarpine release to the tear fluid and for miotic effect. The trans-corneal delivery of the drug was also tested. The overall biol. activity increased in the order series 1 < series 2 < series 3. Hence, the use of a sparingly sol. pilocarpine complex in combination with selected viscous, mucoadhesive hydrogels can result in prolonged activity and increased bioavailability.

ST pilocarpine ophthalmic delivery hydrogel adhesion miosis; eye drop pilocarpine hydrogel adhesion miosis

IT **Tannins**
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(complexes, with pilocarpine; hydrogels viscosity and drug soly. effect on ocular delivery of pilocarpine)

IT Mucins
RL: BPR (Biological process); PRP (Properties); BIOL (Biological study); PROC (Process)
(gastric; hydrogels viscosity and drug soly. effect on ocular delivery of pilocarpine)
IT Adhesion (physical)
Conjunctiva
Drug bioavailability
Eye
Hydrogels (drug delivery systems)
Miosis
Ophthalmic drug delivery systems
(hydrogels viscosity and drug soly. effect on ocular delivery of pilocarpine)
IT 54-71-7, Pilocarpine hydrochloride
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogels viscosity and drug soly. effect on ocular delivery of pilocarpine)
IT 92-13-7D, Pilocarpine, **tannic acid complexes**
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(hydrogels viscosity and drug soly. effect on ocular delivery of pilocarpine)
IT 148-72-1, Pilocarpine nitrate
RL: BPR (Biological process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(hydrogels viscosity and drug soly. effect on ocular delivery of pilocarpine)
IT 9000-69-5, Pectin 9002-89-5, Polyviol W28/20 9004-65-3, Methocel E15LV 11138-66-2, Keltrol TF 37294-28-3, Xyloglucan 76050-42-5, Carbopol 940
RL: MOA (Modifier or additive use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogels viscosity and drug soly. effect on ocular delivery of pilocarpine)

L92 ANSWER 9 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 1996:444021 HCAPLUS
DN 125:85253
TI Absorbents for oxygen as preservatives in beverages
IN Takai, Yuka
PA Toppan Printing Co Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM B01J020-22
ICS A23L003-3436; B01D053-14
CC 17-13 (Food and Feed Chemistry)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08117592	A2	19960514	JP 1994-262690	19941026

AB An oxygen absorbent contains ascorbic acid or its salt, and gallic acid (or benzoic acid, m-hydroxybenzoic acid, p-hydroxybenzoic acid, 2,4-dihydroxybenzoic acid, 3,5-dihydroxybenzoic acid, p-nitrobenzoic acid, terephthalic acid) at pH 4-5, and is used in beverages like fruit juice and sake.
ST oxygen absorbent ascorbate benzoate gallate beverage
IT Beverages
(absorbents for oxygen in beverages)
IT Absorbents
(for oxygen in beverages)
IT 7782-44-7, Oxygen, biological studies 87491-34-7 115973-42-7 178858-62-3 178858-64-5 178858-66-7 178858-68-9 178858-70-3 178858-73-6 178858-76-9 178858-78-1 178858-81-6 178858-83-8 178858-85-0 **178858-86-1** 178858-87-2

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(absorbents for oxygen in beverages)

L92 ANSWER 10 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 1993:538313 HCAPLUS
DN 119:138313
TI Active oxygen free radical removers
IN Kogasaki, Keiichi
PA Sukai Fuudo Kk, Japan
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K035-78
ICS A23L001-30; A61K035-78
CC 18-7 (Animal Nutrition)
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 05139987	A2	19930608	JP 1991-297455	19911113
JP 07112979	B4	19951206		

AB Active O free radical removers contain **epigallocatechin gallate**-contg. green tea leaf exts. and chlorogenic acid-contg. sunflower seed exts. The removers are useful for treatment of inflammation, stroke, arteriosclerosis, cancer, aging, etc. Rats were fed a diet contg. green tea leaf ext. and sunflower seed ext. for 20 days to show remarkable decrease in urinary methylguanidine. Beverages contg. green tea leaf ext. and sunflower seed ext. were manufd.
ST epigallocatechin chlorogenate active oxygen remover; tea sunflower active oxygen remover; anticancer antiinflammatory epigallocatechin chlorogenate; cardiovascular agent epigallocatechin chlorogenate
IT Beverages
Cardiovascular agents
Food
Inflammation inhibitors
Neoplasm inhibitors
(**epigallocatechin gallate** and chlorogenic acid as active oxygen removers for)
IT Reactive oxygen species
RL: BIOL (Biological study)
(removers for, **epigallocatechin gallate** and chlorogenic acid as)
IT Sunflower
(seed, exts., active oxygen removers contg. green tea leaf ext. and)
IT Tea products
(leaves, exts., active oxygen removers contg. sunflower seed ext. and)
IT **149691-10-1**
RL: BIOL (Biological study)
(active oxygen removers contg., of green tea leaf and sunflower seed)
IT 7782-44-7D, Oxygen, reactive species
RL: BIOL (Biological study)
(removers for, **epigallocatechin gallate** and chlorogenic acid as)

L92 ANSWER 11 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 1993:139282 HCAPLUS
DN 118:139282
TI Inhibitory effect of **tannic acid** sulfate and related sulfates on infectivity, cytopathic effect, and giant cell formation of human immunodeficiency virus
AU Mizuno, Takashi; Uchino, Keijiro; Toukairin, Toshikatsu; Tanabe, Akiko; Nakashima, Hideki; Yamamoto, Naoki; Ogawara, Hiroshi
CS Cent. Lab., Nippon Flour Mills Co., Ltd., Atsugi, 243, Japan
SO Planta Med. (1992), 58(6), 535-9
CODEN: PLMEAA; ISSN: 0032-0943

DT Journal
LA English
CC **1-5** (Pharmacology)
AB The acquired immune deficiency syndrome (AIDS) is thought to result from infection of T cells by a pathogenic human retrovirus, human immunodeficiency virus [HIV (HTLV-III/LAV)]. In this report, the authors synthesized sulfated plant polyphenols such as **tannic acid** sulfate, rutin sulfate, ellagic acid sulfate, (-)-**epicatechin** sulfate, and (-)-**epigallocatechin** 3-**gallate** sulfate, and examd. the in vitro inhibitory effect on HIV infection using human T-cell lymphotropic virus type-I-carrying MT-4 cells, which are extremely susceptible to HIV infection. Of the compds. tested, **tannic acid** sulfate was the most effective and had low cytotoxicity. **Tannic acid** sulfate completely inhibited the cytopathic effect of HIV and the HIV-specific antigen expression in MT-4 cells at the concn. of 6 .mu.g/mL. In addn., this sulfate inhibited giant cell formation in coculture at the concn. of 5 .mu.g/mL.
ST polyphenol sulfate human immunodeficiency virus; **tannic acid** sulfate human immunodeficiency virus
IT Virucides and Virustats
(**tannic acid** sulfate and related sulfates as, against HIV)
IT Acquired immune deficiency syndrome
(**tannic acid** sulfate and related sulfates for treatment of)
IT Virus, animal
(human immunodeficiency, **tannic acid** sulfate and related sulfates activity against)
IT **Tannins**
RL: BIOL (Biological study)
(sulfates, HIV infectivity and cytopathic effect and giant cell formation inhibition by)
IT 77271-53-5, Rutin sulfate 114845-21-5 139202-72-5 **146479-42-7**
RL: BIOL (Biological study)
(HIV infectivity and cytopathic effect and giant cell formation inhibition by)
IT 27073-41-2
RL: BIOL (Biological study)
(sulfated, HIV infectivity and cytopathic effect and giant cell formation inhibition by)

L92 ANSWER 12 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 1993:116759 HCAPLUS
DN 118:116759
TI gallic acids as collagenase inhibitors for treatment of periodontosis
IN Inoue, Shintaro; Ota, Hideko; Tonomura, Mikio; Maeda, Masao; Iguchi, Keiji
PA Kanebo, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K031-19
ICS A23G003-00; A23G003-30; A61K007-24; A61K031-235; A61K031-375; C12N009-99
CC 1-9 (Pharmacology)
Section cross-reference(s): 62
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04290819	A2	19921015	JP 1991-76710	19910315

PI JP 04290819 A2 19921015 JP 1991-76710 19910315
OS MARPAT 118:116759
GI



I

AB The collagenase inhibitors gallic acids I (X = H, salt residue, C1-4 alkyl) or their salts are effective in treating periodontosis. Gallic acid, Me gallate, and Et gallate at 1.70, 1.86, and 2.00 .mu.g/mL, resp. inhibited human collagenase by 50%, vs. 0% for isoamyl gallate (0.1 mg/mL). Combination of gallates with ascorbic acid or erythorbic acid showed synergistic effect. Dentifrices and mouthwashes contg. I were formulated.

ST gallate collagenase inhibitor periodontosis treatment; dentifrice gallate collagenase inhibitor; synergism collagenase inhibitor ascorbate erythorbate

IT Dentifrices
Mouthwashes
(contg. gallates, for periodontosis treatment)

IT Periodontium
(disease, periodontosis, treatment of, gallates as collagenase inhibitors for)

IT 9001-12-1, Collagenase
RL: BIOL (Biological study)
(inhibitors for, gallates as, for periodontosis treatment)

IT 50-81-7, Ascorbic acid, biological studies 89-65-6, Erythorbic acid
RL: BIOL (Biological study)
(periodontosis treatment by collagenase inhibitor and)

IT **99-24-1**, Methyl gallate **121-79-9**, Propyl gallate 149-91-7, Gallic acid, biological studies **831-61-8**, Ethyl gallate **1083-41-6**, Butyl gallate **3856-05-1**, Isobutyl gallate 87491-34-7 **146161-88-8** **146161-89-9** **146161-90-2**
RL: BIOL (Biological study)
(periodontosis treatment by, collagenase inhibition in relation to)

L92 ANSWER 13 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 1991:648130 HCAPLUS
DN 115:248130
TI Flavonoids for protection of cells against chemically active species of oxygen, their extraction from plants, and their use in cosmetics
IN Park, Soo Nam; Boo, Yong Chool
PA Pacific Chemical Co., Ltd., S. Korea
SO Fr. Demande, 17 pp.
CODEN: FRXXBL
DT Patent
LA French
IC ICM A61K035-78
ICS A61K031-35
CC **1-12** (Pharmacology)
Section cross-reference(s): 11, 62, **63**

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2651132	A1	19910301	FR 1990-935	19900126
	FR 2651132	B1	19930108		
	KR 9707186	B1	19970507	KR 1989-12435	19890820
	JP 03093782	A2	19910418	JP 1990-16320	19900129
	JP 07103025	B4	19951108		
PRAI	KR 1989-12435	A	19890830		
	KR 1989-12492	A	19890831		

KR 1989-12493 A 19890831
AB Flavonoids are extd. from plants for use as agents to protect cells against chem. active species of O. Cosmetic compns. contain these protective agents. (-)-**Epigallocatechin gallate** (I) was prepd. by extn. from dry leaves of Camellia sinensis L. Galangin was extd. from dry alpinia officinarum Hance roots. In a photohemolysis assay, a 1:1 mixt. of I and galangin gave a half-hemolysis time of >2000 min (compared with 32 min for controls). Each, alone, gave values of 400 and 1800, resp.
ST cell protection oxygen flavonoid plant; cosmetic flavonoid cell protection oxygen; **epigallocatechin gallate** Camellia cell oxygen; galangin Alpinia cell protection oxygen
IT Scutellaria baicalensis
(baicalein of root of, for protection of cells against chem. active forms of oxygen)
IT Flavonoids
RL: BIOL (Biological study)
(cells protection with, from chem. active forms of oxygen)
IT Cosmetics
(contg. plant flavonoids for protection of cells against chem. active forms of oxygen)
IT Tea (Camellia sinensis)
(**epigallocatechin gallate** of, for protection of cells against chem. active forms of oxygen)
IT Leaf
(**epigallocatechin gallate** of, of Camellia sinensis, for protection of cells against chem. active forms of oxygen)
IT Citrus tangerina
Tanaka
(flavonoid of fruit rind of, for protection of cells against chem. active species of oxygen)
IT Acacia catechu
Ginkgo biloba
(flavonoid of leaves of, for protection of cells against chem. active species of oxygen)
IT Alpinia officinarum
(galangin of root of, for protection of cells against chem. active forms of oxygen)
IT Root
(galangin of, of Alpinia officinarum, for protection of cells against chem. active forms of oxygen)
IT Cell
(protection of, against chem. active forms of oxygen, plant flavonoids for)
IT Plant tissue
(rind, flavonoid of, of Citrus tangerina, for protection of cells against chem. active species of oxygen)
IT 491-67-8, Baicalein 548-83-4, Galangin **989-51-5** 137425-06-0 **137425-07-1**
RL: BIOL (Biological study)
(cells protection with, from chem. active forms of oxygen)
IT 117-39-5, Quercetin 153-18-4, Rutin 154-23-4, (+)-Catechin 480-16-0, Morin 480-18-2, Taxifolin 480-20-6, Aromadendrin 480-40-0, Chrysin 480-44-4, Acacetin 490-46-0, (-)-Epicatechin 520-18-3, Kaempferol 520-36-5, Apigenin 525-82-6, Flavone 528-48-3, Fisetin 529-44-2, Myricetin 577-85-5, 3-Hydroxyflavone 604-59-1, 7,8-Benzoflavone 4382-33-6, Dihydrorobinetin 21967-41-9, Baicalin 22888-70-6, Silybin
RL: BIOL (Biological study)
(chem. active oxygen species effect on cells response to)
IT 7782-44-7D, Oxygen, chem.-active forms
RL: BIOL (Biological study)
(flavonoids from plants for protection of cells against)

L92 ANSWER 14 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 1991:185075 HCAPLUS
DN 114:185075

TI Polyphenol interactions. Part 4. Model studies with caffeine and cyclodextrins

AU Cai, Ya; Gaffney, Simon H.; Lilley, Terence H.; Magnolato, Daniele; Martin, Russell; Spencer, Catriona M.; Haslam, Edwin
CS Dep. Chem., Univ. Sheffield, Sheffield, S3 7HF, UK

SO J. Chem. Soc., Perkin Trans. 2 (1990), (12), 2197-209
CODEN: JCPKBH; ISSN: 0300-9580
DT Journal
LA English
CC **26-4** (Biomolecules and Their Synthetic Analogs)
Section cross-reference(s): 22, 33

AB The reversible complexation of phenols and natural polyphenols with caffeine, related heterocycles, and .alpha.- and .beta.-cyclodextrin is examd. Assocn. consts. (K) for 1:1 complexes between caffeine and natural polyphenols are detd. (15-138 dm3 mol-1). Among galloyl esters there is a dependence of strong binding on mol. size, conformational flexibility, and the free galloyl ester group content of the polyphenol. With phenolic flavan-3-ols, assocn. is enhanced by galloylation at C-3. The extent of pptn. of polyphenols by caffeine is related to K, the mol. size of the polyphenol, and the initial concn. of both substrates. Compared with that of the natural galloyl esters (K 76-340 dm3 mol-1), the binding of phenolic flavan-3-ols to .beta.-cyclodextrin is strong (K 210-6231 dm3 mol-1). Models are proposed for encapsulation within the cyclodextin cavity. Hydrophobic effects and hydrogen bonding are discussed.

ST complexation polyphenol caffeine cyclodextrin; assocn phenol caffeine cyclodextrin

IT Overhauser effect
(for polyphenol-cyclodextrin complexes)

IT Hydrogen bond
Molecular association
(of phenols and polyphenols with caffeine and cyclodextrins)

IT Nuclear magnetic resonance
(of phenols and polyphenols, effect of cyclodextrin on)

IT Heat of hydrogen bonding
(of polyphenols with caffeine)

IT 154-23-4, (+)-Catechin 490-46-0, (-)-Epicatechin 970-73-0, (+)-Gallocatechin 970-74-1, (-)-Epigallocatechin **989-51-5** 24808-04-6 **25615-05-8**, (+)-Catechin 3-gallate
RL: PRP (Properties)
(NMR of, effect of cyclodextrin on)

IT 89-86-1, 2,4-Dihydroxybenzoic acid **99-24-1**, Methyl gallate 99-50-3, 3,4-Dihydroxybenzoic acid 99-96-7, properties 100-02-7, p-Nitrophenol, properties 108-46-3, 1,3-Benzenediol, properties 108-73-6, 1,3,5-Benzenetriol 120-80-9, 1,2-Benzenediol, properties **121-79-9**, Propyl gallate 123-31-9, 1,4-Benzenediol, properties 149-91-7, 3,4,5-Trihydroxybenzoic acid, properties 497-76-7 **831-61-8**, Ethyl gallate 2150-43-8, Methyl protocatechuate 3150-24-1, p-Nitrophenyl .beta.-D-galactoside 56128-66-6, Methyl 2,3,4-trihydroxybenzoate
RL: PRP (Properties)
(NMR of, effect of cyclodextrins on)

IT 15155-16-5 24280-36-2 38567-80-5 61955-24-6 61955-25-7 78153-73-8 78153-74-9 78153-75-0 80065-26-5 132367-49-8 **133055-38-6** **133055-39-7** 133055-40-0 133055-41-1 133055-42-2 133055-43-3 133055-44-4 133055-45-5 133055-46-6 133055-47-7 133055-48-8 133055-49-9 133055-50-2 133055-51-3 133055-52-4 133055-53-5 133055-54-6 133055-55-7 133055-56-8 133055-57-9 133055-58-0 133055-60-4 133055-61-5 133055-62-6 133055-63-7 133055-64-8 133055-65-9 133055-66-0 133055-67-1 133055-68-2 133055-69-3 133055-70-6 133055-71-7 133055-72-8 133055-73-9 133055-74-0 133055-75-1 133055-76-2 **133055-77-3** 133055-78-4 133055-79-5 133055-80-8 **133055-81-9** 133055-82-0 133055-83-1 133055-84-2 133055-85-3 133076-07-0 133161-09-8 133161-10-1 133161-11-2 133162-44-4 133267-31-9 133397-37-2
RL: PRP (Properties)

(assocn. const. of)
IT 1333-74-0
RL: RCT (Reactant)
(hydrogen bond, of phenols and polyphenols with caffeine and cyclodextrins)

L92 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2002 ACS
AN 1991:108936 HCAPLUS
DN **114:108936**
TI Transdermal preparations containing **gallic acid** alkyl **esters** as absorption accelerators
IN Tsukahara, Hiroko; Azuma, Masato
PA Sekisui Chemical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K009-70
ICS A61K047-14; A61L015-44; A61L015-58
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 02202813	A2	19900810	JP 1989-23074	19890131
JP 2638635	B2	19970806		

AB Transdermal prepns. contain **gallic acid** C1-18 alkyl **esters** as absorption accelerators. The **esters** are not irritating to the skin and absorbed readily through the skin. Isosorbide nitrate (I) 3, **gallic acid** Pr **ester** (II) 1, and AcOEt soln. contg. 20 wt.% 2-ethylhexyl acrylate-vinylpyrrolidone copolymer 100 wt. parts were mixed, coated on PET film, and dried to give tapes, which were applied to rabbits, resulting in max. plasma concn. of I 65.4 ng/mL 4 h later, vs. 26.8 ng/mL of the control prepd. without II.
ST transdermal **gallic acid** alkyl **ester**
IT **Drug bioavailability**
(of transdermal prepns. contg. **gallic acid** alkyl **esters** as absorption accelerators)
IT Pharmaceutical dosage forms
(tapes, contg. **gallic acid** alkyl **esters** as absorption accelerators)
IT Pharmaceutical dosage forms
(transdermal, contg. **gallic acid** alkyl **esters** as absorption accelerators)
IT 27234-90-8
RL: BIOL (Biological study)
(pharmaceutical tapes contg. **gallic acid** alkyl **ester** and, with good bioavailability)
IT **121-79-9, Gallic acid** propyl **ester**
1034-01-1 1166-52-5, Gallic acid lauryl **ester**
RL: BIOL (Biological study)
(pharmaceutical transdermal prepns. contg., as absorption accelerator)

=> d his l93-

(FILE 'REGISTRY' ENTERED AT 10:24:44 ON 19 JAN 2002)

FILE 'HCAPLUS' ENTERED AT 10:24:56 ON 19 JAN 2002
L93 12 S L92 NOT L59
SEL HIT RN

FILE 'REGISTRY' ENTERED AT 10:25:31 ON 19 JAN 2002
L94 24 S E8-E31
L95 28 S L23,L29,L66

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 10:27:22 ON 19 JAN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:   16 JAN 2002  HIGHEST RN 383858-27-3
DICTIONARY FILE UPDATES:  16 JAN 2002  HIGHEST RN 383858-27-3

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Calculated physical property data is now available.  See HELP PROPERTIES
for more information.  See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d ide can tot l95

L95  ANSWER 1 OF 28  REGISTRY  COPYRIGHT 2002 ACS
RN   291506-36-0  REGISTRY
CN   Benzoic acid, 3,4,5-trihydroxy-, (9E)-9-hexadecenyl ester (9CI)  (CA INDEX
     NAME)
FS   STEREOSEARCH
MF   C23 H36 O5
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Double bond geometry as shown.
```



Hit compounds for reference

```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

              2 REFERENCES IN FILE CA (1967 TO DATE)
              2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE   1:  134:136674

REFERENCE   2:  133:227794

L95  ANSWER 2 OF 28  REGISTRY  COPYRIGHT 2002 ACS
RN   291506-35-9  REGISTRY
CN   Benzoic acid, 3,4,5-trihydroxy-, (6Z,9Z,12Z)-6,9,12-octadecatrienyl ester
     (9CI)  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C25 H36 O5
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Double bond geometry as shown.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:136674

REFERENCE 2: 133:227794

L95 ANSWER 3 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN **291506-34-8** REGISTRY
CN Benzoic acid, 3,4,5-trihydroxy-, (9E,12E,15E)-9,12,15-octadecatrienyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C25 H36 O5**
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:136674

REFERENCE 2: 133:227794

L95 ANSWER 4 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN **291506-33-7** REGISTRY
CN Benzoic acid, 3,4,5-trihydroxy-, (9Z,12Z,15Z)-9,12,15-octadecatrienyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C25 H36 O5**
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:136674

REFERENCE 2: 133:227794

L95 ANSWER 5 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN **291506-32-6** REGISTRY
CN Benzoic acid, 3,4,5-trihydroxy-, (9E,12E)-9,12-octadecadienyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C25 H38 O5**
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:227794

L95 ANSWER 6 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN **291506-31-5** REGISTRY
CN Benzoic acid, 3,4,5-trihydroxy-, (9Z,12Z)-9,12-octadecadienyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C25 H38 O5**
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:136674

REFERENCE 2: 133:227794

L95 ANSWER 7 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN **291506-30-4** REGISTRY
CN Benzoic acid, 3,4,5-trihydroxy-, (9Z)-9-hexadecenyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C23 H36 O5**
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:136674

REFERENCE 2: 133:227794

L95 ANSWER 8 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 188819-08-1 REGISTRY
CN **Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, rel- (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, cis-**
OTHER NAMES:
CN (.+-.)-Epigallocatechin 3-gallate
CN (.+-.)-Epigallocatechol 3-gallate
FS STEREOSEARCH

DR 2596-50-1
MF **C22 H18 O11**
SR CA
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:280620

REFERENCE 2: 129:197563

REFERENCE 3: 126:259162

L95 ANSWER 9 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 137766-94-0 REGISTRY
CN **Benzoic acid, 3,4,5-trihydroxy-, (2S,3S)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, (2S-cis)-**
OTHER NAMES:
CN (+)-Epigallocatechin 3-gallate
CN (+)-Epigallocatechin gallate
FS STEREOSEARCH
MF **C22 H18 O11**
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CHEMCATS, TOXCENTER, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1967 TO DATE)
7 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:280620

REFERENCE 2: 133:310854

REFERENCE 3: 131:314196

REFERENCE 4: 131:120607

REFERENCE 5: 126:220714

REFERENCE 6: 126:84603

REFERENCE 7: 116:734

L95 ANSWER 10 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 130405-40-2 REGISTRY
CN **Benzoic acid, 3,4,5-trihydroxy-, (2S,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Benzoic acid, 3,4,5-trihydroxy-, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester, (2S-trans)-**
OTHER NAMES:
CN (-)-Catechin gallate
FS STEREOSEARCH
MF **C22 H18 O10**
SR CA
LC STN Files: ANABSTR, BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CSCHEM, TOXCENTER, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

52 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
52 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:36568

REFERENCE 2: 136:31686

REFERENCE 3: 135:380367

REFERENCE 4: 135:303146

REFERENCE 5: 135:242062

REFERENCE 6: 135:238128

REFERENCE 7: 135:210069

REFERENCE 8: 135:194757

REFERENCE 9: 135:136564

REFERENCE 10: 135:121339

L95 ANSWER 11 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 107965-88-8 REGISTRY
CN **Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester (9CI)** (CA INDEX NAME)
FS 3D CONCORD
MF **C22 H18 O11**
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:303455

REFERENCE 2: 130:268510

REFERENCE 3: 106:171497

L95 ANSWER 12 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN **36362-22-8** REGISTRY
CN Benzoic acid, 3,4,5-trihydroxy-, (9E)-9-octadecenyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzoic acid, 3,4,5-trihydroxy-, 9-octadecenyl ester, (E)-
FS STEREOSEARCH
MF **C25 H40 O5**
LC STN Files: BEILSTEIN*, CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, TOXCENTER, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:136674

REFERENCE 2: 133:227794

REFERENCE 3: 76:139306

L95 ANSWER 13 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN 25615-05-8 REGISTRY
CN **Benzoic acid, 3,4,5-trihydroxy-, (2R,3S)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Benzoic acid, 3,4,5-trihydroxy-, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester, (2R-trans)-**
CN Catechol, 3-gallate, (+)- (8CI)
CN Gallic acid, 3-ester with catechol, (+)- (8CI)
OTHER NAMES:
CN (+)-Catechin 3-gallate
CN (+)-Catechin 3-O-gallate
CN (+)-Catechin gallate
FS STEREOSEARCH
MF **C22 H18 O10**
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, CA, CAPLUS, TOXCENTER, TOXLIT
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

22 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
22 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:251475

REFERENCE 2: 135:190373

REFERENCE 3: 135:119578

REFERENCE 4: 134:55756

REFERENCE 5: 133:280725

REFERENCE 6: 133:48746

REFERENCE 7: 132:248555

REFERENCE 8: 131:271045

REFERENCE 9: 131:269465

REFERENCE 10: 128:99841

L95 ANSWER 14 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 20819-16-3 REGISTRY
CN **Benzoic acid, 3,4,5-trihydroxy-, (2R,3S)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester, rel- (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Benzoic acid, 3,4,5-trihydroxy-, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester, trans-**
CN Catechol, 3-gallate (7CI, 8CI)
OTHER NAMES:
CN Catechin 3-gallate
CN Catechin gallate
FS STEREOSEARCH
DR 10517-25-6
MF **C22 H18 O10**
LC STN Files: AGRICOLA, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, TOXCENTER, TOXLIT
(*File contains numerically searchable property data)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

22 REFERENCES IN FILE CA (1967 TO DATE)
22 REFERENCES IN FILE CAPLUS (1967 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:47969

REFERENCE 2: 135:232986

REFERENCE 3: 135:194582

REFERENCE 4: 135:24380

REFERENCE 5: 135:14272

REFERENCE 6: 134:366018

REFERENCE 7: 134:83179

REFERENCE 8: 134:55705

REFERENCE 9: 133:263885

REFERENCE 10: 133:251502

L95 ANSWER 15 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 19065-20-4 REGISTRY
CN **Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, trans- (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Gallic acid, 3-ester with gallocatechol, (.+-.)- (8CI)
CN Gallocatechol, 3-gallate, (.+-.)- (8CI)
FS STEREOSEARCH
MF **C22 H18 O11**
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
(*File contains numerically searchable property data)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 71:12957

REFERENCE 2: 68:19544

L95 ANSWER 16 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 17431-25-3 REGISTRY
CN **Benzoic acid, 3,4,5-trihydroxy-, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester, (2S-cis)- (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Epicatechol, 3-gallate, (+)- (8CI)
CN Gallic acid, 3-ester with (+)-epicatechol (8CI)
OTHER NAMES:
CN (+)-Epicatechol 3-gallate
FS STEREOSEARCH
DR 20126-60-7
MF **C22 H18 O10**

LC STN Files: BEILSTEIN*, CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1967 TO DATE)
6 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 126:220714

REFERENCE 2: 123:107779

REFERENCE 3: 116:734

REFERENCE 4: 83:75330

REFERENCE 5: 75:85219

REFERENCE 6: 67:52874

L95 ANSWER 17 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN **15674-66-5** REGISTRY
CN Benzoic acid, 3,4,5-trihydroxy-, (9Z)-9-octadecenyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Gallic acid, (E)-9-octadecenyl ester (8CI)
FS STEREOSEARCH
MF **C25 H40 O5**
LC STN Files: BEILSTEIN*, CA, CAPLUS, TOXCENTER, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:136674

REFERENCE 2: 133:227794

REFERENCE 3: 66:3923

L95 ANSWER 18 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 13445-34-6 REGISTRY
CN **Benzoic acid, 3,4,5-trihydroxy-, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester (9CI)** (CA INDEX NAME)
FS 3D CONCORD
MF **C22 H18 O10**
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 129:267845

L95 ANSWER 19 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN 5127-64-0 REGISTRY
CN **Benzoic acid, 3,4,5-trihydroxy-, (2R,3S)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, (2R-trans)-**
CN Gallic acid, ester with gallocatechol
CN Gallocatechol gallate (6CI)
CN Gallocatechol, 3-gallate (7CI, 8CI)

OTHER NAMES:
CN (+)-Gallocatechol gallate
CN 3-O-Galloyl-(+)-gallocatechin
CN Gallocatechin 3-O-gallate
CN Gallocatechin gallate
FS STEREOSEARCH
DR 36291-30-2
MF **C22 H18 O11**
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, DDFU, DRUGU, NAPRALERT, TOXCENTER, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

75 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
75 REFERENCES IN FILE CAPLUS (1967 TO DATE)
22 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:48394

REFERENCE 2: 136:36568

REFERENCE 3: 136:541

REFERENCE 4: 136:509

REFERENCE 5: 135:285772

REFERENCE 6: 135:232986

REFERENCE 7: 135:216375

REFERENCE 8: 135:205163

REFERENCE 9: 135:194757

REFERENCE 10: 135:97422

L95 ANSWER 20 OF 28 REGISTRY COPYRIGHT 2002 ACS

RN **4233-96-9** REGISTRY
CN **Benzoic acid, 3,4,5-trihydroxy-, (2S,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, (2S-trans)-**
CN Gallic acid, ester with gallocatechol, (-)
CN Gallocatechol, 3-gallate, (-)- (8CI)
OTHER NAMES:
CN (-)-Gallocatechin 3-O-gallate
CN (-)-Gallocatechin gallate
CN (-)-Gallocatechol gallate
CN NVP-XAA 225
FS STEREOSEARCH
MF **C22 H18 O11**
LC STN Files: ANABSTR, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, NAPRALERT, RTECS*, TOXCENTER, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

113 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
113 REFERENCES IN FILE CAPLUS (1967 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:31686

REFERENCE 2: 135:380367

REFERENCE 3: 135:303146

REFERENCE 4: 135:242062

REFERENCE 5: 135:238128

REFERENCE 6: 135:235903

REFERENCE 7: 135:207715

REFERENCE 8: 135:194582

REFERENCE 9: 135:166246

REFERENCE 10: 135:136564

L95 ANSWER 21 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN **1257-08-5** REGISTRY
CN **Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Benzoic acid, 3,4,5-trihydroxy-, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester, (2R-cis)-**
CN Epicatechol, 3-gallate, (-)- (8CI)
CN Epicatechol, gallate (6CI)
CN Gallic acid, 3-ester with epicatechol, (-)- (8CI)
OTHER NAMES:
CN (-)-epi-Catechin 3-O-gallate
CN (-)-Epicatechin 3-gallate
CN (-)-Epicatechin 3-O-gallate
CN (-)-Epicatechol gallate
CN 3-Galloyl-(-)-epicatechin
CN 3-O-Galloyl-(-)-epicatechin
CN 3-O-Galloylepicatechin
CN epi-Catechin 3-O-gallate
CN Epicatechin 3-O-gallate
CN Epicatechin gallate
CN Epicatechol 3-gallate
CN L-Epicatechin gallate
FS STEREOSEARCH
MF **C22 H18 O10**
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CSCHEM, IPA, NAPRALERT, RTECS*, TOXCENTER, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

720 REFERENCES IN FILE CA (1967 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
720 REFERENCES IN FILE CAPLUS (1967 TO DATE)

44 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:47969

REFERENCE 2: 136:36568

REFERENCE 3: 136:34579

REFERENCE 4: 136:31686

REFERENCE 5: 136:31626

REFERENCE 6: 136:509

REFERENCE 7: 136:177

REFERENCE 8: 135:380367

REFERENCE 9: 135:357329

REFERENCE 10: 135:338720

L95 ANSWER 22 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN **1166-52-5** REGISTRY
CN Benzoic acid, 3,4,5-trihydroxy-, dodecyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Gallic acid, dodecyl ester (6CI, 8CI)
OTHER NAMES:
CN Dodecyl 3,4,5-trihydroxybenzoate
CN Dodecyl gallate
CN Gallic acid lauryl ester
CN Lauryl 3,4,5-trihydroxybenzoate
CN Lauryl gallate
CN Nipagallin LA
CN Progallin LA
FS 3D CONCORD
DR 149030-04-6
MF **C19 H30 O5**
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, NIOSHTIC, RTECS*, SPECINFO, TOXCENTER, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

456 REFERENCES IN FILE CA (1967 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

456 REFERENCES IN FILE CAPLUS (1967 TO DATE)
55 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:42534

REFERENCE 2: 136:11208

REFERENCE 3: 136:11151

REFERENCE 4: 135:300632

REFERENCE 5: 135:293977

REFERENCE 6: 135:231498

REFERENCE 7: 135:204919

REFERENCE 8: 135:172948

REFERENCE 9: 135:108911

REFERENCE 10: 135:53458

L95 ANSWER 23 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN **1034-01-1** REGISTRY
CN Benzoic acid, 3,4,5-trihydroxy-, octyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Gallic acid, octyl ester (6CI, 8CI)
OTHER NAMES:
CN n-Octyl gallate
CN Octyl 3,4,5-trihydroxybenzoate
CN Octyl gallate
CN Progallin O
CN Stabilizer GA 8
FS 3D CONCORD
MF **C15 H22 O5**
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MSDS-OHS, NIOSHTIC, RTECS*, TOXCENTER, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

323 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
323 REFERENCES IN FILE CAPLUS (1967 TO DATE)
39 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:42534

REFERENCE 2: 136:11208

REFERENCE 3: 136:11151

REFERENCE 4: 135:293977

REFERENCE 5: 135:277718

REFERENCE 6: 135:204919

REFERENCE 7: 135:151922

REFERENCE 8: 135:137777

REFERENCE 9: 135:108911

REFERENCE 10: 135:41933

L95 ANSWER 24 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN **989-51-5** REGISTRY
CN **Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, (2R-cis)-**
CN Epigallocatechol, 3-gallate (7CI)
CN Epigallocatechol, 3-gallate, (-)- (8CI)
CN Epigallocatechol, gallate (6CI)
CN Gallic acid, 3-ester with epigallocatechol, (-)- (8CI)
OTHER NAMES:
CN (-)-epi-Gallocatechin 3-O-gallate
CN (-)-Epigallocatechin 3-gallate
CN (-)-Epigallocatechin 3-O-gallate
CN (-)-Epigallocatechin gallate
CN (-)-Epigallocatechol gallate
CN 3-O-Galloyl-(-)-epigallocatechin
CN epi-Gallocatechin 3-O-gallate
CN Epigallocatechin 3-gallate
CN Epigallocatechin 3-O-gallate
CN Epigallocatechin gallate
CN L-Epigallocatechin gallate
CN NVP-XAA 723
FS STEREOSEARCH
DR 863-65-0
MF **C22 H18 O11**
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PROMT, RTECS*, SYNTHLINE, TOXCENTER, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1410 REFERENCES IN FILE CA (1967 TO DATE)
18 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1413 REFERENCES IN FILE CAPLUS (1967 TO DATE)
46 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:48387

REFERENCE 2: 136:48310

REFERENCE 3: 136:47969

REFERENCE 4: 136:42549

REFERENCE 5: 136:36568

REFERENCE 6: 136:34579

REFERENCE 7: 136:34578

REFERENCE 8: 136:32982

REFERENCE 9: 136:31686

REFERENCE 10: 136:31626

L95 ANSWER 25 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN **863-03-6** REGISTRY
CN **Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester, rel- (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Benzoic acid, 3,4,5-trihydroxy-, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester, cis-**
CN Epicatechol, 3-gallate (7CI)
CN Gallic acid, 3-ester with epicatechol (8CI)
OTHER NAMES:
CN epi-Catechin 3-O-gallate
CN Epicatechin gallate
CN Epicatechol gallate
FS STEREOSEARCH
MF **C22 H18 O10**
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,

BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, DDFU, DRUGU, EMBASE, MEDLINE, PROMT, TOXCENTER, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

291 REFERENCES IN FILE CA (1967 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
291 REFERENCES IN FILE CAPLUS (1967 TO DATE)
14 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:42549

REFERENCE 2: 136:541

REFERENCE 3: 135:366381

REFERENCE 4: 135:359207

REFERENCE 5: 135:256206

REFERENCE 6: 135:216375

REFERENCE 7: 135:194940

REFERENCE 8: 135:140456

REFERENCE 9: 135:131661

REFERENCE 10: 135:117184

L95 ANSWER 26 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN **149-91-7** REGISTRY
CN Benzoic acid, 3,4,5-trihydroxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Gallic acid (7CI, 8CI)
OTHER NAMES:
CN 3,4,5-Trihydroxybenzoic acid
FS 3D CONCORD
MF C7 H6 O5
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN,

CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TOXLIT, TULSA, ULIDAT, USAN, USPATFULL, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4734 REFERENCES IN FILE CA (1967 TO DATE)
371 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
4748 REFERENCES IN FILE CAPLUS (1967 TO DATE)
19 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:58907

REFERENCE 2: 136:58497

REFERENCE 3: 136:58496

REFERENCE 4: 136:52980

REFERENCE 5: 136:52508

REFERENCE 6: 136:47515

REFERENCE 7: 136:45692

REFERENCE 8: 136:42892

REFERENCE 9: 136:42890

REFERENCE 10: 136:40176

L95 ANSWER 27 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN **121-79-9** REGISTRY
CN Benzoic acid, 3,4,5-trihydroxy-, propyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Gallic acid, propyl ester (6CI, 8CI)
OTHER NAMES:
CN n-Propyl 3,4,5-trihydroxybenzoate
CN n-Propyl gallate
CN Nipa 49
CN Nipagallin P
CN Nipanox S 1
CN PG
CN Progallin P
CN Propyl 3,4,5-trihydroxybenzoate
CN Propyl gallate
CN Tenox PG
FS 3D CONCORD
DR 56274-95-4
MF **C10 H12 O5**
CI COM

LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TOXLIT, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2041 REFERENCES IN FILE CA (1967 TO DATE)
17 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2042 REFERENCES IN FILE CAPLUS (1967 TO DATE)
150 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:45424

REFERENCE 2: 136:42866

REFERENCE 3: 136:42790

REFERENCE 4: 136:42534

REFERENCE 5: 136:32996

REFERENCE 6: 136:32663

REFERENCE 7: 136:20568

REFERENCE 8: 136:19274

REFERENCE 9: 136:18006

REFERENCE 10: 136:11208

L95 ANSWER 28 OF 28 REGISTRY COPYRIGHT 2002 ACS
RN **99-24-1** REGISTRY
CN Benzoic acid, 3,4,5-trihydroxy-, methyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Gallic acid, methyl ester (6CI, 8CI)
OTHER NAMES:
CN 3,4,5-Trihydroxybenzoic acid methyl ester
CN Methyl 3,4,5-trihydroxybenzoate
CN Methyl gallate
FS 3D CONCORD
MF **C8 H8 O5**
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HODOC*,

IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PIRA, RTECS*, SPECINFO, TOXCENTER, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

615 REFERENCES IN FILE CA (1967 TO DATE)
22 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
616 REFERENCES IN FILE CAPLUS (1967 TO DATE)
34 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:31380

REFERENCE 2: 135:295980

REFERENCE 3: 135:289857

REFERENCE 4: 135:258228

REFERENCE 5: 135:251475

REFERENCE 6: 135:242454

REFERENCE 7: 135:220669

REFERENCE 8: 135:207225

REFERENCE 9: 135:206895

REFERENCE 10: 135:205163